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Introduction: Although guidelines do not recommend chemotherapy for patients with
advanced cancer when death is imminent, many reports suggest the tendency to continue
this treatment has been increasing every year. This study aimed to construct a model to
clarify the beliefs and communication of doctors who administer chemotherapy to patients
with recurrent or metastatic (hereafter, “recurrent/metastatic”) breast cancer, and determine
how these beliefs are related to the process of treating patients.
Materials and methods: Semi-structured interviews were conducted with 21 breast
surgeons, and interview contents were analyzed using the grounded theory approach in
order to conceptualize the treatment process.
Results: The process of chemotherapy for patients with recurrent/metastatic breast cancer
differed based on two beliefs held by doctors. One was a “belief that the patient is an entity
who cannot accept death,” and throughout the treatment process, these doctors consistently
avoided sharing bad news that might hurt patients, and always discussed aggressive che-
motherapy. They proposed treatments as long as options remained, and when they ultimately
judged that the physical condition of patients could not withstand further treatment, treatment
was terminated despite the patient hoping for continuation. The other was a “belief that the
patient is an entity who can accept death.” From early on after recurrence/metastasis, these
doctors repeatedly gave patients information including bad news about prognosis, and when
they judged that further treatment would hinder a patient’s ability to have a good death, they
proposed terminating treatment.
Conclusion: We demonstrated that breast surgeons treating recurrent/metastatic breast
cancer patients have two beliefs and constructed a model of the treatment process based
on those beliefs. This offered breast surgeons, who make decisions regarding treatment
without clearly-deﬁned guidelines, a chance to reﬂect on their own care style, which we
believe will contribute to optimal patient care.
Keywords: palliative chemotherapy, end-of-life, decision-making process, qualitative
research
Introduction
Although guidelines of the American Society of Clinical Oncology do not recom-
mend chemotherapy when patients are near death, chemotherapy is continued in
some cases until immediately before death. Numerous reports suggest that this trend
is increasing every year.1–3 Several studies have reported that these decisions to
continue chemotherapy are inﬂuenced by the beliefs held by doctors and their
background,4 as well as by a “never give up” relationship fostered between doctors
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and patients.5 While some studies have touched on patterns
of the treatment process and terminal stage continuation or
suspension of chemotherapy,6 the manner in which these
patterns are inﬂuenced by the physician’s thinking has not
been addressed.
Against this backdrop, the present study examined
breast surgeons who perform palliative chemotherapy for
patients with recurrent or metastatic (hereafter, “recurrent/
metastatic”) breast cancer, aiming to clarify their beliefs,
how these beliefs relate to patient-doctor communication,
and the treatment process leading from a diagnosis of
recurrence/metastasis to patient death. The aim was to
construct a model of relationships between the beliefs
held by doctors, the palliative chemotherapy process, and
patient-doctor communication.
The ﬁrst reason we narrowed our focus to breast cancer
is that breast cancer is highly sensitive to chemotherapy,
and the disease appears in patients at a relatively young
age. Because these characteristics have been identiﬁed as
factors associated with doctors continuing chemotherapy
into the terminal stage,3 we believed it to be highly likely
that breast surgeons would propose aggressive anti-cancer
therapy for these patients. The second reason is the variety
of anti-cancer therapies from which to choose when treat-
ing patients with breast cancer recurrence/metastasis.
Thus, compared to other cancers, if one treatment is inef-
fective, other options to continue treatment exist.
Methods
Participants
Participants were board certiﬁed breast specialists with a
track record of treating breast cancer with chemotherapy in
Japan. In Japan, doctors who specialize in this area tend to
be surgeons rather than oncologists, and perform diagnosis,
surgery, and chemotherapy. In selecting participants, we
performed theoretical sampling combined with snowball
sampling and, in order to collect data in as wide a range
as possible (in terms of afﬁliated hospital size, record of
treating patients, personal history and gender, and access to
resources in palliative medicine). All participants gave their
written informed consent for participate in this study. This
study was approved by the research ethics committee of the
University of Tokyo Faculty of Medicine (No. 10,317).
Data collection
All interviews were conducted by one of the authors
(ROH). ROH is a physician and has experience working
in a department of palliative medicine, and holds a PhD in
qualitative research, and thus is well versed in qualitative
studies. In terms of participant background (Table 1), there
were 16 men and 5 women, with a median age of 48 years
(range, 35–56 years). Semi-structured interviews were
conducted in a private room to ensure privacy, for an
average of 86 mins (range, 70–120 mins).
An interview guide was created based on previous
research on diverse cancer patients as well as pilot interviews
to breast surgeons. Participants were questioned about their
thoughts and experiences about their practices of deciding
chemotherapy for breast cancer recurrence/metastasis.
During a later phase of the study, the interview guide was
revised to include questions about communication with
patients and family members regarding prognosis (Box 1).
Data analysis
All interviews were audio taped and transcribed verbatim.
The process of data collection and analysis followed the
Grounded Theory Approach.7 Verbatim records of inter-
views were analyzed using ATLAS.ti.7.1.7 (Science
Software Development GmbH, Berlin). Open Coding,
Axial Coding, and Selective Coding were performed.
Concepts were generated to explain the decision-making
process of doctors regarding chemotherapy, and additional
data were collected to develop these concepts. Data collec-
tion and analysis were continued until theoretical satura-
tion was reached.7 To ensure credibility of the analytical
process and analytical results, periodic peer debrieﬁngs
were held with colleagues who conduct qualitative
research.8 In addition, member checks9 were conducted,
ie, the authors explained the preliminary analysis report to
two participants for feedback.
Results
Two beliefs about accepting death
The process by which the chemotherapy of patients with
recurrent/metastatic breast cancer was continued and termi-
nated differed based on two beliefs held by doctors (Figure 1).
One of these is a “belief that the patient is an entity who cannot
accept death” (hereafter “non-acceptance belief”). Doctors
with the non-acceptance belief maintained that bad news
could harm patients, focused ﬁrst only on discussions of
anti-cancer therapy, and avoided any discussions that might
suggest death. They proposed treatments as long as options
were available, and ultimately when it was determined that the
patient’s physical condition could not bear further treatment,
Ozeki-Hayashi et al Dovepress
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they ended it in order to avoid doing harm, although they kept
patients still hoping for continued treatment. The other is a
“belief that the patient is an entity who can accept death”
(hereafter “acceptance belief”). Doctors with this belief pro-
vided patients with an overview of their conditions early on
following the diagnosis of recurrent/metastatic breast cancer.
They repeatedly prepared patients for bad news about the
progression of the illness or termination of treatment from
early in the treatment process, and ultimately, when they
judged that administering the next treatment would make it
impossible for patients to achieve their own good death pro-
cesses, they proposed terminating treatment.
Table 1 Doctor background
ID Age Years
of experience
Sex Specialista Palliative careb Hospital functionc
1 40’s 15 M Spec. PCT/PCU Cancer
2 40’s 19 M Spec./Onco PCT University
3 30’s 9 M Cert. PCT/PCU Cancer
4 40’s 24 M Spec. No General
5 40’s 17 M Spec. PCT/PCU Cancer
6 50’s 27 F Spec. PCT General
7 50’s 27 M Spec. PCT General
8 50’s 30 F Spec. PCT General
9 40’s 22 M Spec. PCT University
10 50’s 30 F Spec. PCT University
11 40’s 23 M Spec. PCT General
12 40’s 20 F Spec. PCT General
13 30’s 11 M Cert. PCT Cancer center
14 30’s 13 M Spec. PCT University
15 40’s 16 M Spec./Onco PCT/PCU Cancer center
16 50’s 22 F Spec. PCT Cancer center
17 40’s 20 M Spec. PCT General
18 50’s 30 M Spec. PCT/PCU Cancer center
19 50’s 30 M Spec. PCT General
20 50’s 24 F Spec. PCT University
21 30’s 13 M Spec. PCT General
Notes: aAcquisition of breast specialization: Cert. (Board Certiﬁed member of The Japanese Breast Cancer Society), Spec. (Specialist of The Japanese Breast Cancer
Society), Onco (Diplomate, Subspecialty Board of Medical Oncology, JSMO), bHospital Palliative Care Resource: PCT (Palliative Care Team), cHospital: Cancer (Designated
cancer hospital), University (University hospital), General (General hospital), Cancer center (National cancer center)
Abbreviation: PCU, Palliative Care Unit.
Box 1 Set of interview questions
#1 Story of how you became a breast surgeon.
#2 Process from initiating to concluding treatment of patients with recurrent/metastatic breast cancer.
#3 What is discussed before treatment begins?
#4 As a surgeon, how do you feel when cancer recurs (in a patient you operated on)?
#5 Your evaluation of the guidelines (what do you think about second and third line treatment)?
#6 How do you view the response rate in clinical trials and drugs covered by insurance?
#7 When and how do you convey the future outlook or that a cure will be difﬁcult?
#8 Do you explain the option of non-treatment? (Why?)
#9 How do you talk about the termination of treatment? (Speciﬁcally)
#10 Methods of conﬁrming patient intent, methods of communication
#11 In what sort of communication about prognosis do you engage?
#12 How do you consult with patients regarding early and terminal palliative care, etc.?
#13 How do you feel about the fact that patients will inevitably die?
#14 Resistance to dealing with death in the course of providing care, and past experiences with it
#15 Is there anything you want to add? Is there anything that you want to say more about?
Dovepress Ozeki-Hayashi et al
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Non-acceptance belief narratives
First, doctors with the non-acceptance belief considered
patients unable to accept death, and avoided discussions
with patients that involved confronting death.
For Japanese people, I think it’s hard to end life in a way
that simply accepts death. There are few who have the
strength to face death, and even fewer doctors who are
willing to accompany them as they do so. (ID8)
Many had a sense of powerlessness and guilt toward
patients whose cancer relapsed after they performed sur-
gery, and thus, as surgeons, were adamant about continu-
ing chemotherapy. They stated that, as the person who
understands patients the best, they wanted to continue to
be in charge of their care until the very end. This kind of
doctor believed that it was the surgeon’s mission to con-
tinue to support the life of patients with treatment.
My feeling is that really the stance of the surgeon is to be
proactive about surgery and to always think about how to
do things better. (ID7)
Acceptance belief narrative
On the other hand, doctors with the acceptance belief
considered patients to be able to accept death, and aspired
for communication that would support patients as they
face death. They believed that the relationship of trust
with patients required a sharing of an overarching perspec-
tive on the disease that included death.
By giving patients some picture of what the illness will be
like in advance, I think they can make their own judg-
ments, or maybe by doing that, even when I have to give
them bad news, they would be able to accept it. (ID15)
Furthermore, this group believed that the doctor’s mis-
sion was to keep supporting patients so they could
experience a good death. They believed it most important
to ensure that patients are able to spend their ﬁnal days as
they wish.
It (the doctor’s goal) is all about ﬁnding how we can
support patients during the time they have left before
they die. (ID12)
  
Informing patients of
anti-cancer therapy options
Recurrence
or
metastasis
PS0~1 1~2 2~3 3~4
 “Let’s take a break from
treatment”
Breaking bad news
Step 3A
Step 2
Step 3B
Step 4
PC
Patient
death
Palliative care
(PC)
Breaking
bad news
Preparation for
breaking bad news
Early sharing of bad
news with patients
Acceptance
belief
Non-
acceptance
belief
Termination of
treatment so the
patient can have
a good death
Continuation of
treatment to test
efficacy
Step 1
Continuation of
treatment to
prolong life
Continuation of
treatment to
satisfy patient
and doctor
Suspension of
treatment to
avoid harm
Figure 1 The process based on two beliefs.
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Four steps for decision-making process
of chemotherapy for advanced breast
cancer patients
Step1
In Step 1, the doctor continues treatment to prolong life.
When recurrence/metastasis is diagnosed, the ﬁrst treat-
ment option is chemotherapy, unless hormone therapy is
indicated. Regardless of their beliefs, many doctors
encouraged patients to undergo treatment, believing there
is evidence that the initial treatment (ﬁrst through third
line treatment) prolongs life.
At this stage, doctors with the non-acceptance belief
conveyed to patients that the illness will not get better, but
many prioritized discussing speciﬁc anti-cancer therapies,
rather than sharing an overview of the illness, which
includes death.
When it recurs, I ﬁrst discuss the necessary anti-cancer
therapy. (ID14)
On the other hand, doctors with the acceptance belief
shared with patients an overview of the illness that implies
death will inevitably come, in order to build a relationship
of trust with patients.
I make it a point to clearly tell them that if the cancer
comes back, they will die eventually. Maybe I do this to
avoid any misunderstanding. (ID12)
Step2
In Step 2, treatment is continued in order to test its poten-
tial efﬁcacy. In the case of breast cancer patients, physical
condition is often good even after failing the fourth line of
treatment, and although the evidence of their efﬁcacy is
inadequate, multiple treatment options exist. Doctors,
however, out of mistrust of current evidence or a belief
that any drug approved and covered by public medical
insurance must have at least some minimal effect,
entrusted their hopes to any therapy that has a non-zero
chance of working, and continued treatment.
It’s not as if there’s evidence that the treatment will never
work. (ID15)
Oncologists stress the evidence, but breast surgeons want
to provide patients with any treatment that would not do
harm. There are also patients who want to try any treat-
ment if it might have some effect. (ID 11)
At this point, doctors with the non-acceptance belief felt a
resistance to discussing prognosis, and rarely shared the
prognosis with patients. Doctors with the acceptance
belief, however, were prepared to discuss all bad news,
and at times shared an outlook on prognosis with patients.
If patients want to know how long they have left (prognosis), I
feel I should tell them how long I think they have to live. (ID2)
Step3A
Step 3 comes into play after failing the ﬁfth line of treat-
ment, and doctors already predict that the next treatment
would not be effective. At this step, doctors with the non-
acceptance belief continued treatment in order to satisfy
patients, hoping the treatment would have a positive psy-
chological effect (Step 3A). At this stage, doctors stressed
satisfying patients by continuing treatment, rather than the
effect of the chemotherapy itself.
The point of treatment is to give peace of mind, for the
patient’s sake. (ID21)
Because doctors at this stage emphasized patient safety,
they administered a reduced dosage when the patient’s
physical condition was bad, even if it weakened the anti-
cancer effect. At this stage, continuing treatment is thought
to have the psychological effect of offering salvation to
maintain hope, or to help patients understand through
experience that their condition is progressing and that
treatment will no longer have an effect.
‘We did all we could, but it didn’t work; there’s nothing
more to do,’ I want patients to come to that conclusion on
their own. (ID4)
Furthermore, participants believed that fulﬁlling the
wishes of patients would also satisfy the doctor. In the
backdrop of this was the desire to live up to their ideal
vision of the doctor as one who can fulﬁll patient hopes by
always proactively proposing treatments. These doctors
were conﬁdent that a surgeon could manage pain relief
and end-of-life care. In addition, when continuing to diag-
nose and treat patients they had operated on, as surgeons,
there was a sense of guilt at having allowed the cancer to
return, and a feeling of powerlessness at being unable to
heal it, leading them to insist on further chemotherapy. For
this reason, they believed that the mission of doctors is to
support the life of patients until the very end, motivating
the continuation of treatment.
When cancer returns in patients I operated on, I feel guilty.
That’s why I want to do something (chemotherapy) for
them. (ID18)
Dovepress Ozeki-Hayashi et al
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Among these doctors, there was a tendency to avoid
clearly conﬁrming patient intent regarding treatment, out
of a sense of resistance toward convincing the patient to
give up treatment. Inferring the desire of patients to con-
tinue treatment, they suggest it as long as patients did not
refuse, or alternatively did not recommend treatment but
conveyed this in a way that left room for continuing
treatment.
As long as they don’t say they want to stop, we keep
proposing options. (ID7)
Even when patients ask about prognosis, these doctors
often did not clearly share it to avoid hurting them.
Reasons for this included the difﬁculty of prognosis in
breast cancer, or that it was not necessary to inform
patients because they should have already realized, or
that doctors hope the patients would guess the prognosis
on their own during the course of treatment.
When continuing the treatment of metastasis or recur-
rence, I think patients probably know that it’s natural
that the treatment will stop working, and realizes that
this is harsh, and risky. So, as a doctor, I think, ok, it’s
time to notice the signs. (ID9)
These doctors, however, sometimes looked back at the
results of continued treatment at this stage and regretted
the decisions made, wishing they had not gone through
with the ﬁnal treatment.
You wonder if it might have been better not to proceed
with that last treatment. (ID4)
Step3B
On the other hand, doctors with the acceptance belief
terminated treatment for the sake of allowing patients to
have a good death (Step 3B). These doctors drew on
information gleaned from discussions with patients until
that point, and when it seemed highly likely that the next
treatment would make it impossible for them to have a
good death, they would propose giving up on treatment in
favor of palliative medicine.
If we pursue treatment, there is the possibility that patients
might not be able to do the things that are most precious to
them, so I let them know that it’s better not to do it (anti-
cancer therapy). (ID16)
Many patients accepted such proposals, and anti-cancer
therapy was terminated to focus solely on palliative med-
icine, so that the case does not progress to Step 4. When
patients had difﬁculty accepting death, and strongly
requested that treatment be continued, doctors respected
these intentions and attempted treatment for a limited
period. When treatment was found not to be effective,
however, these doctors proposed terminating treatment,
and almost all patients accepted this.
If someone really wants to continue, I say ok, let’s do our
best. But this is the last thing we’ll do, I explain. I tell
them that if this doesn’t work, we quit. (ID15)
Some doctors with the acceptance belief had this kind of
experience with patients: as a result of their attempts to
persuade a patient to terminate anti-cancer therapy and
focus on palliative care, the patient stops coming to the
hospital and transfers to a different hospital in order to
continue treatment.
(After even the patient mentioned wanting to proceed with
treatment) The husband asked me to ‘just go on and do it
for her.’ I explained that it was better to value the time
remaining (rather than continuing treatment), but they
said, ‘Fine, we will go to another hospital,’ and the patient
died just one month after transferring. (ID17)
Step4
When the illness worsened to the point that chemotherapy
would be dangerous, doctors with the non-acceptance
belief decided they could not perform treatments that
would only harm patients, and paused treatments in order
to avoid harm (Step 4).
At this time, while doctors sometimes told patients
they could not offer any more treatment, they did show a
sense of consideration to protect patients from the harsh
reality of facing death, and so framed their proposal as
“Let’s take a break from treatment for a bit.” This allowed
patients to maintain hope that treatment would be re-
initiated, while effectively ending treatment.
When treatment was virtually impossible to continue, I
would say something like ‘Why not take a little break?’
This is different than saying that no more treatment would
be performed. (ID6)
Discussion
Beliefs of doctors and the anti-cancer
therapy process
In this study, we identiﬁed two beliefs held by doctors who
treat recurrent/metastatic breast cancer—the acceptance
Ozeki-Hayashi et al Dovepress
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belief and non-acceptance belief—and created a model for
the treatment process and communication shaped by dif-
ferences in these beliefs. Pirl et al categorized the process
of terminating chemotherapy in the terminal stage into (1)
a ﬁnal decision to clearly terminate treatment, (2) an
ambiguous termination of treatment through postponement
of the decision, and (3) a “non-decision” that leaves treat-
ment terminated.10 Doctors of the present study who held
the acceptance belief followed (1), whereas doctors with
the non-acceptance belief almost always followed (2) or
(3). The research by Pirl et al, however, merely classiﬁed
patterns. The present study is unique in that it clariﬁed the
underlying unconscious thoughts of doctors.
Overprotection model in patient-doctor
relationships
Among doctors who held the non-acceptance belief, there
were those who, not wanting to hurt patients, inferred that
the intent of patients was a “desire for treatment” and thus
continued to propose treatment options. Doctors taking this
approach consistently throughout the process of treating
patients with recurrent/metastatic breast cancer may have hin-
dered the psychological growth of patients because, if they had
adequately discussed the issues during the process, patients
may have come to accept and understand death. This resem-
bles the type of overprotection that occurs when mothers
obstruct their children’s process of growth and autonomy in
order not to harm them. In this study, we refer to this type of
patient-doctor relationship as “the overprotection model”.
One model of patient-doctor relations in which doctors
make decisions against patient wishes or by inferring intent is
paternalism, but “the overprotection model” is different.
Paternalism can be divided into “hard paternalism” in
which doctors know the patient’s intent but go against it
nonetheless, and “soft paternalism”, when doctors do not
know the patient’s intent but they or patient family members
make decisions thought to be best for patients.11 In the over-
protectionmodel we propose, doctors impede patient growth.
Doctors make decisions based on their unconscious beliefs,
as they do not believe the patient’s ability to grow, and deny
the possibility of growth through the process of facing a good
death. In other words, the doctor’s stance is not to deny the
patient’s intent, but to deny growth of the patient as a human,
which differs from traditional paternalism.
If, under the overprotection model, the patient’s idea of a
good death is to die without facing death, and this matches
what doctors infer is a good death, then this model could be
beneﬁcial. Some have noted, however, that there may be
patients who, even though they display nothing but rejection
or anger when initially diagnosed, will come to grow, achieve
autonomy, and accept death through the process of interacting
with their doctors.12,13 Although this study did not delve into
the drawbacks of adopting the overprotection model, we
believe they would be substantial. Future studies that examine
the effects of the overprotection model and include patients
and bereaved family members as participants are warranted.
Clinical implications
Table 2 shows the 10 categories identiﬁed in this study,
which serve as clues as to which belief the doctors them-
selves hold when they approach treatment. Based on
whether there were more As or Bs, we considered it
possible to determine that a doctor’s beliefs were closer
to “acceptance” for A or “non-acceptance” for B (though
there may of course be doctors who hold both beliefs).
Below we describe notable points for each belief.
For doctors closer to the non-acceptance belief
Try to share patient values to the extent possible
Doctors with the non-acceptance belief tended to avoid talk-
ing to patients about death, because they thought it would
Table 2 Clues as to which belief the doctors themselves hold when they approach treatment beliefs
Acceptance group ・Often discusses not just treatment but bad news, outlook
・Makes an effort to prepare to talk about bad news
・Has experienced being told by patients that they want to discuss bad news early
・Has experienced sharing bad news with patients who were able to accept a good death
・Good collaboration with palliative medicine, palliative care team
Non-acceptance group ・Discussing bad news will worsen relationship with patients, or has worsened it
・Patients are happier if they can make it to the end of life without considering death
・Often end treatment by saying, “let’s take a little break from treatment”
・Thinks palliative medicine alone will not prolong patient life
・Feels guilty about postoperative recurrence
Dovepress Ozeki-Hayashi et al
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cause suffering. It is possible that, for individual patients,
these doctors were unable to acquire information about what
the patient considered a “good death”. Although it might be
difﬁcult to share accurately the patient’s idea of what con-
stitutes a good death, the sense that doctors understand their
thoughts is a major source of support for patients. In recent
years, Advance Care Planning (ACP) has broadened ways of
not only sharing patient intentions about treatment, but even
sharing their value systems. There have been reports that
ACP has increased the satisfaction of terminal patients and
their family members.14 Thus, the sharing of values, not only
through ACP, could provide valuable support to patients.
Coordinating treatment with the palliative care team
Disclosing bad news on disease outlook, including death, is a
difﬁcult and stressful kind of communication for doctors.15–17
Particularly when a doctor is in charge of the care of a single
patient over a long period, it can be very difﬁcult for them to
discuss the terminal stage.16 Temel et al reported that when
discussing terminal stage care, an introduction to the palliative
care team can be a valuable source of support.18 For doctors
who resist discussing end of life, promptly informing patients
about the palliative care team, and letting patients know about
preparations to coordinate treatment with palliative care team,
can potentially relieve doctors’ stress around disclosing around
bad news.
For doctors closer to the acceptance belief
Awareness of individual differences in “good death” desired
by patients
Among doctors with the acceptance belief, there were a few
whose values strongly insisted that only by accepting death
could patients meet a good death, and thus they appeared not
to address individual differences in what a good death might
mean. In a previous qualitative study on patients with meta-
static breast cancer, some patients were found to be over-
whelmed by the fear of death, see treatment as a lifeline, and
hope to continue treatment for as long as possible in order to
forestall death.19 There is also a report that for some cancer
patients, treatment is used as a form of life support and way
of coping with the fear of death; when treatment is stopped, it
eases the strain on the body, but leaves emotional stress.20
That study also suggested that continuing chemotherapy at a
dosage that would not impact the patient physically might
offer salvation to such patients. In cases where patients
absolutely desire to continue treatment even after discussions,
it may be prudent to examine how to respect the patient’s
conception of a good death.
Limitations
This study has some limitations. First, because we did not
survey the views of patients or bereaved family members,
we could not determine the impact of the treatment pro-
cess or doctor’s thinking on their QOL in the terminal
stage. In this regard, surveys that include patients and
family members and assessing their connection to the
treatment process and doctor’s way of thinking would be
informative. Second, the present study is a qualitative
study focused on Japanese breast surgeons, and the results
are dependent on Japanese treatment practices and indivi-
dual contexts. For this reason, gauging the generalizability
of these results in other medical cultures and contexts will
require an expanded scope, for example global quantitative
research. By drawing from the rigorous procedures of the
Grounded Theory Approach, however, this study has elu-
cidated the target phenomenon in great detail.
Conclusion
This study identiﬁed two beliefs regarding the patient’s
acceptance of death among breast surgeons treating recur-
rent/metastatic cancer, and constructed a model of the term-
inal stage treatment process, consisting mainly of palliative
chemotherapy and patient-doctor communication, based on
relationships with these two beliefs. We propose that doctors
who hold these beliefs, even partially, heed three points in the
course of clinical practice: the need to share the patient’s
value system, the need to consider how best to make use of
the palliative care team, and the need to be conscious of
individual differences in what the patient regards as a good
death. We believe this would contribute to the ability of
doctors, who make decisions about chemotherapy at the
end stage for breast cancer patients in the absence of
clearly-deﬁned guidelines, to offer patients optimal care.
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